Published in Ther Apher Dial on June 01, 2004
Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure. Dig Dis Sci (2010) 1.78
Initial combination anti-viral therapy with lamivudine and adefovir dipivoxil decreases short-term fatality rate of hepatitis-B-virus-related acute-on-chronic liver failure. Virol J (2015) 0.77
Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int (2005) 2.26
Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int (2009) 2.10
Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol (2012) 1.95
Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis (2004) 1.93
Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial (2005) 1.78
Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis (2011) 1.69
Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan. Am J Kidney Dis (2012) 1.68
Retracted Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: a COOPERATE-ABP substudy. Am J Nephrol (2004) 1.57
Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant (2011) 1.55
Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract (2005) 1.46
Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients. Am J Hypertens (2008) 1.46
Spontaneous remission of severe hyperparathyroidism with normalization of the reversed whole PTH/intact PTH ratio in a haemodialysis patient. Nephrol Dial Transplant (2007) 1.41
Carvedilol ameliorates low-turnover bone disease in non-obese type 2 diabetes. Am J Nephrol (2011) 1.41
Serum pro-hepcidin as an indicator of iron status in dialysis patients. Ther Apher Dial (2008) 1.40
p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. Kidney Int (2013) 1.31
Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int (2005) 1.31
Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis (2004) 1.29
FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int (2009) 1.25
Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis (2004) 1.23
Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia. Nephrol Dial Transplant (2005) 1.16
Histomorphometric analysis of diabetic osteopenia in streptozotocin-induced diabetic mice: a possible role of oxidative stress. Bone (2006) 1.14
Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients. Ther Apher Dial (2013) 1.14
Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant (2011) 1.12
Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol Dial Transplant (2009) 1.11
Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol (2010) 1.09
Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients. Am J Nephrol (2011) 1.03
The role of FGF23 in CKD--with or without Klotho. Nat Rev Nephrol (2012) 1.02
Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol (2014) 1.01
Role of oxidative stress in diabetic bone disorder. Bone (2009) 1.01
A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol Dial Transplant (2013) 1.01
Changes in chemical composition of cortical bone associated with bone fragility in rat model with chronic kidney disease. Bone (2011) 1.01
Prevalence and cardiovascular features of Japanese hemodialysis patients with Fabry disease. Am J Nephrol (2009) 1.00
Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan. J Bone Miner Res (2013) 1.00
Role of oxidative stress and indoxyl sulfate in progression of cardiovascular disease in chronic kidney disease. Ther Apher Dial (2011) 0.99
The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice. Atherosclerosis (2008) 0.99
A possible role of thioredoxin interacting protein in the pathogenesis of streptozotocin-induced diabetic nephropathy. Kobe J Med Sci (2007) 0.98
A human serum albumin-thioredoxin fusion protein prevents experimental contrast-induced nephropathy. Kidney Int (2013) 0.97
Bone formation in spontaneously diabetic Torii-newly established model of non-obese type 2 diabetes rats. Bone (2007) 0.96
Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats. Nephrol Dial Transplant (2006) 0.95
Overproduction and secretion of a novel amino-terminal form of parathyroid hormone from a severe type of parathyroid hyperplasia in uremia. Clin J Am Soc Nephrol (2006) 0.94
Impact of parathyroidectomy on serum FGF23 and soluble Klotho in hemodialysis patients with severe secondary hyperparathyroidism. J Clin Endocrinol Metab (2014) 0.94
Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism. Nephron Clin Pract (2005) 0.94
Mineral and bone disorders outcomes study for Japanese chronic kidney disease stage 5D patients: rationale and study design. Ther Apher Dial (2011) 0.93
Large carboxy-terminal parathyroid hormone (PTH) fragment with a relatively longer half-life than 1-84 PTH is secreted directly from the parathyroid gland in humans. Eur J Endocrinol (2003) 0.93
Diseases of the parathyroid gland in chronic kidney disease. Clin Exp Nephrol (2011) 0.92
Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. Nephrol Dial Transplant (2005) 0.92
Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia. Kidney Int (2003) 0.92
Oxidative and nitrosative stress and progression of diabetic nephropathy in type 2 diabetes. Am J Nephrol (2010) 0.91
Overexpression of thioredoxin1 in transgenic mice suppresses development of diabetic nephropathy. Nephrol Dial Transplant (2007) 0.91
Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus. Intern Med (2013) 0.90
Vitamin D activates the Nrf2-Keap1 antioxidant pathway and ameliorates nephropathy in diabetic rats. Am J Hypertens (2013) 0.90
The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: a 1-year prospective observational study. Nephrol Dial Transplant (2011) 0.90
Sequential changes in plasma intact and whole parathyroid hormone levels during parathyroidectomy for secondary hyperparathyroidism. World J Surg (2005) 0.90
Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis (2002) 0.90
p-Cresyl sulfate induces osteoblast dysfunction through activating JNK and p38 MAPK pathways. Bone (2013) 0.88
Association between indoxyl sulfate and skeletal resistance in hemodialysis patients. Ther Apher Dial (2010) 0.88
Source matters: from phosphorus load to bioavailability. Clin J Am Soc Nephrol (2011) 0.88
Effect of beta(2)-microglobulin adsorption column on dialysis-related amyloidosis. Kidney Int (2003) 0.87
New insights into the role of fibroblast growth factor 23 in chronic kidney disease. J Nephrol (2010) 0.87
Composition and plaque patterns of coronary culprit lesions and clinical characteristics of patients with chronic kidney disease. Kidney Int (2012) 0.87
Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns. Clin J Am Soc Nephrol (2011) 0.86
In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3. Nephrol Dial Transplant (2003) 0.86
Adenoendocrine cell carcinoma of the gallbladder clinically mimicking squamous cell carcinoma. Int J Clin Oncol (2009) 0.86
Comparison of parathyroid hormone levels from the intact and whole parathyroid hormone assays after parathyroidectomy for primary and secondary hyperparathyroidism. Surgery (2004) 0.86
Accumulated uremic toxins attenuate bone mechanical properties in rats with chronic kidney disease. Bone (2013) 0.86
Heme-oxygenase upregulation ameliorates angiotensin II-induced tubulointerstitial injury and salt-sensitive hypertension. Am J Nephrol (2006) 0.86
Comparison between whole and intact parathyroid hormone assays. Ther Apher Dial (2011) 0.85
Efficacy of long-acting insulin analog insulin glargine at high dosage for basal-bolus insulin therapy in patients with type 2 diabetes. Tokai J Exp Clin Med (2012) 0.85
Is hepcidin the star player in iron metabolism in chronic kidney disease? Kidney Int (2009) 0.85
With or without the kidney: the role of FGF23 in CKD. Nephrol Dial Transplant (2005) 0.85
Putative role of endothelial lipase in dialysis patients with hypoalbuminemia and inflammation. Am J Nephrol (2008) 0.85
Evaluation of bioartificial renal tubule device prepared with lifespan-extended human renal proximal tubular epithelial cells. Nephrol Dial Transplant (2012) 0.85
Mineral and bone disorders in kidney transplant recipients: reversible, irreversible, and de novo abnormalities. Clin Exp Nephrol (2015) 0.85
Regression of parathyroid hyperplasia by calcimimetics--fact or illusion? Nephrol Dial Transplant (2008) 0.84
IRMA (whole PTH) is a more useful assay for the effect of PTH on bone than the Allegro intact PTH assay in CAPD patients with low bone turnover marker. Nephrol Dial Transplant (2003) 0.84
Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride. Nephrology (Carlton) (2011) 0.84
CKD Clinical Practice Guidebook. The essence of treatment for CKD patients. Clin Exp Nephrol (2009) 0.83
Altered expression of aquaporins 1 and 4 coincides with neurodegenerative events in retinas of spontaneously diabetic Torii rats. Exp Eye Res (2009) 0.83
[The pleiotropic effects of vitamin D on kidney disease]. Clin Calcium (2007) 0.83
Sphingosine 1-phosphate stimulates rat mesangial cell proliferation from outside the cells. Nephrol Dial Transplant (2002) 0.83
Effects of Cyclophosphamide Pulse Therapy on the Clinical and Histopathological Findings, Particularly Crescent Formation, in a Patient with Adult-onset Steroid-refractory Henoch-Schönlein Purpura Nephritis. Intern Med (2015) 0.82
Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients. Nephrol Dial Transplant (2003) 0.82
Development of bioartificial renal tubule devices with lifespan-extended human renal proximal tubular epithelial cells. Nephrol Dial Transplant (2011) 0.82
Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis. Contrib Nephrol (2013) 0.82
Relationship between parathyroid hormone and cardiac abnormalities in chronic dialysis patients. Intern Med (2007) 0.82
Uremic toxins and oral adsorbents. Ther Apher Dial (2011) 0.82
Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study. Ther Apher Dial (2008) 0.82
Diabetes mellitus suppresses hemodialysis-induced increases in tear fluid secretion. BMC Res Notes (2014) 0.82
Role of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism. Ther Apher Dial (2005) 0.82
Fibroblast growth factor-23 in patients with Graves' disease before and after antithyroid therapy: its important role in serum phosphate regulation. J Clin Endocrinol Metab (2005) 0.82
Clinical characteristics and cardiovascular outcomes of hemodialysis patients with atrial fibrillation: a prospective follow-up study. Am J Nephrol (2011) 0.82
The negative Ca(2+) balance is involved in the stimulation of PTH secretion. Nephron (2002) 0.82
Effects of raloxifene on bone mineral metabolism in postmenopausal Japanese women on hemodialysis. Ther Apher Dial (2011) 0.81
Effects of AST-120 on left ventricular mass in predialysis patients. Am J Nephrol (2011) 0.81